Hanmi Sees Double Again: Files For Combination Of Sanofi’s Aprovel And Pfizer’s Lipitor
This article was originally published in PharmAsia News
A deal with Sanofi draws upon a 2009 co-marketing deal by Hanmi with Merck & Co. Inc. to pave the way.
You may also be interested in...
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.